The year of 2002 was marked by  the founding of Radiopharmacus – Solutions in Nuclear Medicine, specialized in provide consulting services in hospital radiopharmacy.


In 2004, by investing in technology with a view to offering innovative solutions for the market, the company moved to TECNOPUC – PUC/RS (located in Porto Alegre, Rio Grande do Sul state, Brazil), ones of the largest technology parks in Latin America.


Started  Cold Kits manufacturing in an industrial scale.


First round of Venture Capital investment.


Investment in the new brand: we become the RPH Group.

In the same year RPH Group has set partnership  with ITG (Isotope Technologies Garching), introducing the new Ga-68 technology in the Brazilian nuclear medicine market.




In 2014 the company’s manufacturing plant obtained GMP certification (Good Manufacturing Practices), becoming the first in its sector to achieve this certification  according to national legislation.


Portfolio within the regulatory requirements of ANVISA, including Lantheus generator.


RPHOSTEO (medronic acid) is the first Cold Kit to receive a market authorization in the history of Brazilian radiopharmacy.

In the same year, RPH Central Pharma, the first centralized radiopharmacy in Brazil, was inaugurated in São Paulo.


RPHKARDIA (MIBI) is the second cold kit to receive its registration in the Brazilian radiopharmacy.

RPH Pharma has invested heavily in the expansion of its manufacturing plant, increasing its production capacity and enabling the expansion of its participation in the international market.


Renewal of the GMP Certificate of the Porto Alegre plant.

The RPHNEFRO (DTPA) is the third cold kit to receive your registration.

Beginning of works on the second unit of RPHCENTRALPHARMA, which will be located in the city of Rio de Janeiro, RJ